{"id":579336,"date":"2026-02-10T07:35:16","date_gmt":"2026-02-10T07:35:16","guid":{"rendered":"https:\/\/www.europesays.com\/us\/579336\/"},"modified":"2026-02-10T07:35:16","modified_gmt":"2026-02-10T07:35:16","slug":"hims-hers-collapses-after-fda-vows-to-restrict-copycat-glp-1-pill-is-the-stock-toast","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/579336\/","title":{"rendered":"Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?"},"content":{"rendered":"\n

The telehealth company Hims & Hers<\/strong> (NYSE: HIMS), which provides consultations and prescriptions, saw its stock crater by nearly 16% on Feb. 9 after deciding not to move forward with plans to offer a copycat GLP-1 pill.<\/p>\n

This decision was made after U.S. Food and Drug Administration last Friday announced its “intent to take decisive steps to restrict GLP-1 active pharmaceutical<\/a> ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims & Hers and other compounding pharmacies — as similar alternatives to FDA-approved drugs.”<\/p>\n

Will AI create the world’s first trillionaire?<\/strong>\u00a0Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need.\u00a0Continue \u00bb<\/strong><\/a><\/p>\n

\"Person Image source: Getty Images. <\/p>\n

Hims & Hers has previously sold an injectable weight-loss treatment that used compounded semaglutide, the active ingredient in Novo Nordisk’s<\/strong> Ozempic and Wegovy, which are used to help suppress appetite and aid weight loss. Novo Nordisk then created a version of Wegovy in pill form that would cost $149 per month.<\/p>\n

Hims & Hers last week announced a copycat version of the Wegovy pill that would cost $49 for the first month and $99 per month after on a five-month plan. That sent the stock surging last week, but shortly after the announcement, Novo Nordisk announced plans to sue Hims & Hers for patent infringement, which led the stock to give up those gains.<\/p>\n

Hims & Hers’ stock is now down over 58% in the past year. Is the company toast?<\/p>\n

Through the first nine months of 2025, Hims & Hers grew revenue by 74% year over year, driven largely by demand for the company’s alternative weight-loss treatments.<\/p>\n

The stock shot higher on several occasions in 2025 but has since pulled back, likely due to concerns about the sustainability of the company’s revenue from GLP-1 drugs<\/a>. <\/p>\n

Hims & Hers has called Novo Nordisk’s lawsuit a “blatant attack” on “millions of Americans who rely on compounded medications for access to \u200cpersonalized care… Once again, big pharma is weaponizing the U.S. judicial system to \u200blimit consumer choice.”<\/p>\n

However, the FDA seems serious about cracking down on copycat drugs, and the agency’s specific naming of Hims & Hers is not a good sign.<\/p>\n

Given the intense demand for GLP-1 drugs and increasing competition, prices for these drugs are likely to come down over time, which would make the business tougher, even if Hims & Hers manages to escape current regulatory and legal issues. Furthermore, the telehealth market, which was a darling during the pandemic, has lost some of its appeal and faces significant competition.<\/p>\n

I don’t necessarily know if Hims & Hers is toast, but I would avoid the stock right now to let the legal and regulatory concerns play out.<\/p>\n

Before you buy stock in Hims & Hers Health, consider this:<\/p>\n

The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a><\/strong> for investors to buy now\u2026 and Hims & Hers Health wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n

Consider when Netflix<\/strong> made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you\u2019d have $443,299<\/strong>!* Or when Nvidia<\/strong> made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,136,601<\/strong>!*<\/p>\n

Now, it\u2019s worth noting\u00a0Stock Advisor\u2019s total average return is 914% \u2014 a market-crushing outperformance compared to 195% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors.<\/strong><\/p>\n

See the 10 stocks \u00bb<\/strong><\/a><\/p>\n

*Stock Advisor returns as of February 9, 2026. <\/p>\n

Bram Berkowitz<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy<\/a>.<\/p>\n

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?<\/a> was originally published by The Motley Fool<\/p>\n","protected":false},"excerpt":{"rendered":"The telehealth company Hims & Hers (NYSE: HIMS), which provides consultations and prescriptions, saw its stock crater by…\n","protected":false},"author":3,"featured_media":579337,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[210,251402,1060,9412,67,132,68],"class_list":["post-579336","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-hims-hers","tag-medication","tag-novo-nordisk","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116045187212355838","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/579336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=579336"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/579336\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/579337"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=579336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=579336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=579336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}